Latest from MSKCC

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.
Steven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.
C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.
Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).
Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.
The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.
Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.
Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin to improve outcomes for these patients.
Publication Bottom Border
Border Publication